XORTX Therapeutics Inc (XRTX NASDAQ) stock market data APIs
$2.6496
0.07(2.6%)
as of May 7, 2026
Try our APIs with
free plan!
XORTX Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.
Prev. Close
2.6496
Open
2.7186
High
2.8424
Low
2.6212
52 wk Range
1.725-7.05
Market Cap
4 100 K
Shares Outstanding
1 547 K
EPS
-0.4507
Beta
0.223
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get XORTX Therapeutics Inc data using free add-ons & libraries
Get XORTX Therapeutics Inc Fundamental Data
XORTX Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -2 508 489
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-02
- EPS/Forecast: -1.58
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
XORTX Therapeutics Inc News
New
XORTX Closes Acquisition Of Kidney Anti-fibrotic Asset From Vectus; Stock Down
(RTTNews) - XORTX Therapeutics Inc. (XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announced the closing ...
XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset
• VB4-P5 – novel new chemical entity with potential to address significant unmet need in rare and large-market chronic kidney disease • CALGARY, Alberta, April 13, 2026 (GLOBE NEWSWIRE) -- XO...
XORTX Announces Results of Annual and Special Meeting of Shareholders
CALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Announces Share Consolidation
CALGARY, Alberta, March 25, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
Get XORTX Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
